Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Pulmonary Hypertension, Pulmonary Thromb...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary hypertension is a serious and progressive disease that is difficult to treat and diagnose, mainly because its symptoms are nonspecific and often delay recognition. Early diagnosis is a major challenge. Although several tests may suggest the disease, the definitive diagnosis still requires right heart catheterization, an invasive procedure that directly measures pulmonary hemodynamics such as pulmonary artery pressure, cardiac output, and vascular resistance. Electrical impedance tomography (EIT) is a non-invasive, radiation-free bedside monitoring method that can evaluate ventilation and pulmonary perfusion. The number of studies investigating perfusion with EIT has been increasing, since the possibility of having a safe, radiation-free, and repeatable method available at the bedside is of great clinical interest in different fields of medicine. Our hypothesis is that EIT provides information that correlates with the findings of right heart catheterization in patients with suspected pulmonary arterial hypertension (PAH). EIT may serve as a useful screening tool prior to catheterization and may also help in risk stratification of patients with pulmonary hypertension

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Electrical Impedance Tomography (EIT) — Non-invasive, radiation-free bedside monitoring of ventilation and pulmonary perfusion. Patients will be monitored for a short period using EIT, with data analyzed offline to assess pulsatility and perfusion indices.
  • Procedure: Right Heart Catheterization — Standard invasive hemodynamic assessment performed for clinical indication, including measurement of pulmonary artery pressure, cardiac output, pulmonary vascular resistance, and stroke volume. Used as the gold standard comparator for EIT-derived measures.

Primary Outcomes

  • Sensitivity (%) of Electrical Impedance Tomography (EIT)-Derived Pulsatility Amplitude for Detection of Pulmonary Hypertension Defined by Mean Pulmonary Artery Pressure (At the time of right heart catheterization (baseline, single assessment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-26
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Contact Information
Study Contact:
Marcelo BP Amato, MD PhD
+55113061-7361
marcelo.amato@hc.fm.usp.br
Jade Lara de Melo, PT
+5534992911757
jade.l.melo.l@gmail.com
Marcelo BP Amato, MD, PhD
+55113061-7361
marcelo.amato@hc.fm.usp.br
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP
Interventions
  • Diagnostic Test: Electrical Impedance Tomography (EIT) — Non-invasive, radiation-free bedside monitoring of ventilation and pulmonary perfusion. Patients will be monitored for a short period using EIT, with data analyzed offline to assess pulsatility and perfusion indices.
  • Procedure: Right Heart Catheterization — Standard invasive hemodynamic assessment performed for clinical indication, including measurement of pulmonary artery pressure, cardiac output, pulmonary vascular resistance, and stroke volume. Used as the gold standard comparator for EIT-derived measures.
Study Locations (1 sites)
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, São Paulo 05403-900 Brazil
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis or clinical suspicion of pulmonary arterial hypertension (PAH) and with a medical indication for right heart catheterization. * Patients evaluated at the Pulmonology Service of InCor-HCFMUSP. Exclusion Criteria: * Pregnancy. * Structural heart disease, such as atrial septal defect, ventricular septal defect, or valvular disease. * Cardiac arrhythmias. * Presence of a cardiac pacemaker or other implantable electronic device. * Skin lesions at the thoracic region that would prevent placement of the EIT electrode belt. * WHO functional class IV of new york heart association (NYAH).. * Inability to perform a voluntary respiratory pause (apnea) of at least 30 seconds or inability to understand and follow instructions required. * Decline to participate in the study by not signing the informed consent form or refusal by the attending medical team.
Conditions Respiratory Failure, Critical Illness
Phase Not Applicable
Enrollment 1680
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Sedation is frequently required in critically ill patients admitted to the intensive care unit (ICU), including those receiving non-invasive respiratory support such as high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or conventional oxygen therapy. Anxiety, agitation, dyspnea, and poor tolerance of respiratory support may compromise treatment adherence and increase the risk of respiratory deterioration and endotracheal intubation. Appropriate sedation may improve patient comfort, facilitate respiratory support, and reduce complications. However, sedation in non-mechanically ventilated ICU patients remains challenging because excessive sedation may lead to respiratory depression or hemodynamic instability. Propofol is commonly used for ICU sedation because of its rapid onset and controllable depth of sedation. Nevertheless, propofol is associated with several adverse effects, including respiratory depression, hypotension, and injection pain, which may limit its use in patients without invasive mechanical ventilation. Ciprofol is a novel short-acting intravenous sedative that acts as a gamma-aminobutyric acid type A (GABA-A) receptor agonist and is structurally related to propofol. Previous studies have demonstrated that ciprofol has rapid onset, predictable sedation, less injection pain, and a potentially lower incidence of respiratory depression and hemodynamic instability compared with propofol. Clinical studies have shown favorable safety and efficacy profiles of ciprofol in procedural sedation, anesthesia induction, and sedation in mechanically ventilated ICU patients. However, evidence regarding its use in ICU patients receiving non-mechanical ventilation is still limited. This study aims to compare the effectiveness and safety of ciprofol versus propofol for sedation in adult ICU patients who are not receiving invasive mechanical ventilation. The study will be conducted as a multicenter retrospective cohort study involving approximately 30 tertiary hospitals in China. Adult ICU patients treated between January 1, 2022 and July 30, 2024 who received intravenous sedation with either ciprofol or propofol while receiving non-invasive respiratory support (including NIV, HFNC, or conventional oxygen therapy) will be included. The primary outcomes are sedation success rate and the incidence of respiratory depression. Sedation success is defined as maintaining the Richmond Agitation-Sedation Scale (RASS) within the target range of -2 to +1 for at least two consecutive hours without discontinuation of the sedation regimen or switching to another sedative. Respiratory depression will be defined based on predefined criteria including severe hypoxemia, markedly reduced respiratory rate, abnormal end-tidal carbon dioxide levels, or apnea. Secondary outcomes include endotracheal intubation rate during the sedation period, ICU length of stay, ICU mortality, and the requirement for vasoactive agents. Propensity score matching and…

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Sedation Success Rate (From initiation of sedation up to 72 hours during ICU stay.)
  • Incidence of Respiratory Depression (From initiation of sedation up to 72 hours during ICU stay.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-24
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1680 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
zhenhua zeng, doctor
+86 18529269527
hzengzhu@163.com
zhenhua zeng, doctor
+86 18529269527
hzengzhu@163.com
Nanfang Hospital, Southern Medical University
Interventions
N/A
Study Locations (1 sites)
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515 China
Eligibility Criteria
Inclusion Criteria Age: * Age ≥18 years * Admitted to the intensive care unit (ICU) between January 1, 2022 and July 30, 2024 * Received intravenous sedation with either ciprofol or propofol during ICU stay * Total duration of ciprofol or propofol administration ≥2 hours * Sedation initiated while the patient was not receiving invasive mechanical ventilation * Receiving non-invasive respiratory support or oxygen therapy at the time sedation was started, including noninvasive ventilation (NIV), high-flow nasal cannula (HFNC), nasal cannula, or face mask oxygen therapy * Availability of complete electronic medical records including sedation assessment using the Richmond Agitation-Sedation Scale (RASS) * Availability of continuous vital sign monitoring records including respiratory rate, oxygen saturation, blood pressure, and heart rate Exclusion Criteria: * Age \<18 years * Pregnancy or breastfeeding * Use of other primary sedative agents during the observation period, including midazolam or dexmedetomidine * Total exposure time to ciprofol or propofol \<2 hours * Known allergy or hypersensitivity to ciprofol, propofol, or their formulation components * Initiation of invasive mechanical ventilation before sedation * Missing key clinical data required for outcome evaluation, including sedation score, vital signs, or drug administration records * Participation in other interventional clinical trials that may interfere with outcome assessment * Severe visual or hearing impairment preventing accurate sedation assessment * Coma or conditions that prevent reliable evaluation using the Richmond Agitation-Sedation Scale (RASS) * Any condition that the investigators consider inappropriate for inclusion in the study
Conditions Asthma Childhood, Asthma, Inhalation Spa...
Phase NA
Enrollment 208
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is one of the most common chronic diseases in children, and treatment success often depends on proper inhaler use and consistent medication adherence. Exposure to allergens and pollutants can also impact treatment response and asthma control. Moreover, there is a growing need for non-invasive biomarkers to support better diagnosis and personalized care. The goal of this clinical trial is to investigate if a new digital inhaler can improve inhalation technique and treatment adherence in children aged 5 to 16 years old, with partly controlled or uncontrolled asthma requiring treatment with inhaled corticosteroids. The main questions it aims to answer are: * Does the use of a digital inhaler improve adherence to inhaled corticosteroids and asthma control in children? * Which biomarkers could support diagnosis and help predict treatment responses in children with asthma? * How do environmental factors influence asthma control and treatment outcomes? Researchers will compare adherence to inhaled corticosteroid therapy between children using a new digital inhaler (Whizz spacer) and those using a standard, non-digital inhaler (AeroChamber Plus® Flow-Vu®) to see if the digital inhaler improves treatment administration and asthma control. They will quantify inflammatory markers in biological samples from asthmatic children and children without respiratory disease, to find biomarkers linked to disease and treatment response. Participants will: * Use the Whizz spacer or the AeroChamber Plus® Flow-Vu® during 12 weeks for corticosteroid inhalation, and complete daily a study diary to follow treatment administration. * Complete asthma control and quality of life questionnaires and have an evaluation of asthma control through GINA score at baseline, 6 and 12 weeks. * Undergo spirometry tests and FENO measurements at baseline and 12 weeks. * Give biological samples at baseline and 12 weeks. * Collect children's bedroom dust samples at baseline. * Wear a bracelet for 7 days at baseline and 12 weeks to monitor physical activity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Whizz spacer system — Whizz spacer is a new digital valved holding chamber that is intended to administer aerosolized medication from the metered dose inhaler to the patient. It allows monitoring of treatment administration through light indicators and a mobile application.
  • Device: AeroChamber Plus® Flow-Vu® — AeroChamber Plus® Flow-Vu® is a standard valved holding chamber used to administer aerosolized medication from the metered dose inhaler to the patient.

Primary Outcomes

  • Measurement of inhaled corticosteroid therapy adherence and comparison between the two spacers (From enrolment to the end of the intervention at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-02
Completion: 2027-08
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 208 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Luxembourg Institute of Health
Collaborators: Luxembourg National Research Fund, Centre Hospitalier du Luxembourg, Meracle Health (Luxembourg) S.à.r.l
Principal Investigators:
  • Christiane Hilger, PhD (PRINCIPAL_INVESTIGATOR) - Luxembourg Institute of Health
Contact Information
Study Contact:
Christiane Hilger, PhD
+352 26970258
christiane.hilger@lih.lu
Ali Znati
+352 26970-811
ALi.Znati@lih.lu
Ali Znati
+352 26970-811
ALi.Znati@lih.lu
Luxembourg Research Clinic (LRC)
Interventions
  • Device: Whizz spacer system — Whizz spacer is a new digital valved holding chamber that is intended to administer aerosolized medication from the metered dose inhaler to the patient. It allows monitoring of treatment administration through light indicators and a mobile application.
  • Device: AeroChamber Plus® Flow-Vu® — AeroChamber Plus® Flow-Vu® is a standard valved holding chamber used to administer aerosolized medication from the metered dose inhaler to the patient.
Study Locations (1 sites)
Luxembourg Research Clinic (LRC), Luxembourg, Luxembourg
Eligibility Criteria
Inclusion Criteria: * Patient aged between 5-16 years, male or female * Physician diagnosis of asthma requiring a controller treatment with ICS or ICS/Long-acting beta-agonists (LABA) via MDI * Partly controlled or uncontrolled asthma based on GINA criteria and definitions * Informed consent signed by legally authorized representatives (LAR) and assent from young patient (only applicable for children ≥ 10 years) Exclusion Criteria: * Patients with severe asthma exacerbation treated with systemic corticosteroids within the last 2 weeks or patients with active respiratory tract infection * Diagnosis of underlying chronic lung disease other than asthma (e.g., BPCO/cystic fibrosis etc.) * Severe asthma based on GINA definitions * Severe underlying disorders ((severe congenital heart disease, oncologic patients) (non-exhaustive list, left to the evaluation of the PI)) * Immune deficiency or under immunosuppressive treatments * In receipt of immunotherapy (only for participants in Luxembourg donating samples for biomarker research) * Patients with neurological diseases / impaired cognitive disorder * Siblings of patients already included in the study
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase PHASE4
Enrollment 178
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Glycemic Variability of Combination Therapies in T2DM

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Empagliflozin/Metformin — 5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
  • Drug: Anagliptin — 100 mg, for 12 weeks (PO, BID)
  • Drug: Metformin — 500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
  • Drug: Empagliflozin/Linagliptin — 10/5 mg, for 12 weeks (PO, QD)

Primary Outcomes

  • Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12 (Baseline to week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-29
Completion: 2027-03-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 178 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: JW Pharmaceutical
Principal Investigators:
  • Sung Rae Kim (PRINCIPAL_INVESTIGATOR) - The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
Contact Information
Study Contact:
Saemi Kang
82-2-840-6902
kangsm@jwhealthcare.com
Sung Rae Kim
82-32-340-7013
kimsungrae@catholic.ac.kr
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
Interventions
  • Drug: Empagliflozin/Metformin — 5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
  • Drug: Anagliptin — 100 mg, for 12 weeks (PO, BID)
  • Drug: Metformin — 500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
  • Drug: Empagliflozin/Linagliptin — 10/5 mg, for 12 weeks (PO, QD)
Study Locations (1 sites)
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor. Exclusion Criteria: * History of acute or chronic metabolic acidosis * Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²) * Severe hepatic impairment * History of heart failure (NYHA Class III/IV)
Conditions Anxiety Disorders, Stress Disorders, Pos...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pregnant and postpartum patients hospitalized for medical complications experience high rates of depression, anxiety, and trauma-related symptoms, yet access to timely psychiatric care during obstetric hospitalization is limited. Project MOCHA integrates early mental health screening, trauma-informed psychotherapy, and structured follow-up into routine inpatient maternity care for individuals at elevated clinical risk. This single-arm implementation study examines the feasibility, acceptability, and fidelity of delivering a Collaborative Mental Health Care Program within a high-risk obstetric inpatient setting. The program includes brief inpatient psychotherapy, symptom monitoring, and post-discharge follow-up over three months. Preliminary changes in depression, anxiety, attention-deficit hyperactivity disorder, and posttraumatic stress symptoms will be assessed to inform future effectiveness trials and broader health system integration.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Collaborative Mental Health Care Program (CMHCP) — The CMHCP intervention provides mental health support to pregnant and postpartum patients hospitalized for medical complications on a high-risk obstetric unit. After enrollment, participants complete a brief mental health questionnaire. During their hospital stay, participants may receive brief individual therapy sessions delivered in person and adapted to medical needs and length of stay. Therapy uses trauma-informed strategies to support emotional well-being. Participants complete short symptom check-ins during hospitalization, and some may receive optional telehealth sessions if additional support is needed. Participants are contacted about three months after discharge for follow-up to assess mental health symptoms and well-being.

Primary Outcomes

  • Change in depressive symptoms measured by the Edinburgh Postnatal Depression Scale (EPDS) (From baseline (hospital admission) to 3 months post-discharge)
  • Change in anxiety symptoms measured by the Generalized Anxiety Disorder 7 (GAD-7) (From baseline (hospital admission) to 3 months post-discharge)
  • Change in posttraumatic stress symptoms measured by the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) (From baseline (hospital admission) to 3 months post-discharge)
  • Feasibility of weekly symptom screening during hospitalization (During hospitalization (from admission to discharge))
  • Acceptability of psychotherapy sessions measured by the Session Rating Scale (SRS) (During hospitalization (from admission to discharge))
  • Fidelity to psychotherapy protocol: percentage of scheduled sessions delivered (During hospitalization (from admission to discharge))
  • Acceptability of the MOCHA program measured by the Client Satisfaction Questionnaire (CSQ-8) (3 months post-discharge)
  • Change in symptoms of Attention Deficit Hyperactivity Disorder as measured by Adult ADHD Self-Report Scale (From baseline (hospital admission) to 3 months post-discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-07-15
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Indiana University
Principal Investigators:
  • Tiffany R Williams, PhD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Tiffany R Williams, PhD
317-963-7300
tw84@iu.edu
Tiffany R Williams, PhD
317-963-7300
tw84@iu.edu
Riley Hospital for Children at Indiana University Health
Angela G Campbell, PhD
anggcamp@iu.edu
Riley Hospital for Children at Indiana University Health
Interventions
  • Behavioral: Collaborative Mental Health Care Program (CMHCP) — The CMHCP intervention provides mental health support to pregnant and postpartum patients hospitalized for medical complications on a high-risk obstetric unit. After enrollment, participants complete a brief mental health questionnaire. During their hospital stay, participants may receive brief individual therapy sessions delivered in person and adapted to medical needs and length of stay. Therapy uses trauma-informed strategies to support emotional well-being. Participants complete short symptom check-ins during hospitalization, and some may receive optional telehealth sessions if additional support is needed. Participants are contacted about three months after discharge for follow-up to assess mental health symptoms and well-being.
Study Locations (1 sites)
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana 46202 United States
Eligibility Criteria
Inclusion Criteria: * 18 years old or older * Pregnant (or recently have given birth) at any gestational age * Must have experienced at least one adverse pregnancy outcome * Admitted for an extended inpatient stay * English speaking Exclusion Criteria: * Under 18 years old * Not currently pregnant or past one year postpartum * Not experienced at least one adverse pregnancy outcome * Not admitted for an extended inpatient stay at RMT
Conditions Endoscopic Video-assisted Nipple-sparing...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Endoscopic video-assisted nipple-sparing mastectomy (E-NSM) is an advancement in minimally invasive breast surgery designed to reduce surgical trauma and improve cosmetic outcomes while maintaining strict oncologic safety. The procedure will be carried out by a dedicated surgical team in which at least one operator holds certified laparoscopic surgical training issued by a recognized scientific society, ensuring appropriate technical expertise and adherence to surgical safety standards.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic video-assisted nipple-sparing mastectomy (E-NSM) — Endoscopic video-assisted nipple-sparing mastectomy (E-NSM) is an advancement in minimally invasive breast surgery designed to reduce surgical trauma and improve cosmetic outcomes while maintaining strict oncologic safety. Recent prospective studies and meta-analyses have shown encouraging results in terms of technical feasibility, reduced flap-related complications, and higher patient satisfaction compared with the conventional open approach.

Primary Outcomes

  • Rate of completion of the procedure endoscopically without conversion to open surgery. (At surgery)
  • Surgery time (At surgery)
  • Feasibility of immediate reconstruction (At surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-23
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Contact Information
Study Contact:
Eleonora Meduri, MD
+39 02 57489 725
eleonora.meduri@ieo.it
Eleonora Meduri, MD
+39 02 57489 725
eleonora.meduri@ieo.it
Istituto Europeo di Oncologia
Eleonora Meduri, MD
Istituto Europeo di Oncologia
Interventions
  • Procedure: Endoscopic video-assisted nipple-sparing mastectomy (E-NSM) — Endoscopic video-assisted nipple-sparing mastectomy (E-NSM) is an advancement in minimally invasive breast surgery designed to reduce surgical trauma and improve cosmetic outcomes while maintaining strict oncologic safety. Recent prospective studies and meta-analyses have shown encouraging results in terms of technical feasibility, reduced flap-related complications, and higher patient satisfaction compared with the conventional open approach.
Study Locations (1 sites)
Istituto Europeo di Oncologia, Milan, 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥18 years * Candidates for nipple-sparing mastectomy (NSM) with immediate reconstruction * Histologically confirmed invasive carcinoma cT1N0, or carriers of pathogenic germline mutations undergoing prophylactic mastectomy * Breast size I-III and absence of significant glandular ptosis * Signed informed consent Exclusion Criteria: * Inflammatory breast cancer * Locally advanced clinical stage (cT2-T4 or N+) * Ductal carcinoma in situ (DCIS) without invasive component * Previous radiotherapy to the affected breast * Locoregional recurrence * Clinical conditions contraindicating prosthetic reconstruction * Indication for skin-sparing (SSM) or skin-reducing mastectomy (SRM) * Ongoing or completed neoadjuvant chemotherapy before surgery * Refusal or inability to sign informed consent * Inability to complete scheduled follow-up
Conditions Breast Cancer, Sarcoma, Gastric (Stomach...
Phase PHASE2
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Riluzole — Given PO
  • Other: Placebo — Given PO

Primary Outcomes

  • Change in circulating Brain-Derived Neurotrophic Factor (BDNF) levels over time in cancer patients receiving chemotherapy (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-23
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Irvine
Principal Investigators:
  • Alexandre Chan, PharmD, MPH (PRINCIPAL_INVESTIGATOR) - Chao Family Comprehensive Cancer Center
Contact Information
Study Contact:
Chao Family Comprehensive Cancer Center University of California, Irvine
877-827-8839
ucstudy@uci.edu
University of California Irvine Medical
Interventions
  • Drug: Riluzole — Given PO
  • Other: Placebo — Given PO
Study Locations (1 sites)
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California 92868 United States
Eligibility Criteria
Inclusion Criteria: * Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen. * ≥18 years of age. * Life expectancy \> 6 months * Able to provide informed consent. * Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance. Exclusion Criteria: * Presence of primary brain tumors or brain metastases. * Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy. * Unwilling to undergo neuropsychological assessments necessary for the study. * Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy. * History of or suspected hypersensitivity to riluzole or to any of its excipients. * Patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole. * Hepatic impairment as indicated by: AST and/or ALT ≥ 3 X upper limit normal (ULN). * Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.
Conditions Blood Pressure Monitoring, Hypertension ...
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to find out whether an enhanced program works better than remote blood pressure monitoring (RBPM) alone for women who had high blood pressure during pregnancy. The enhanced program combines RBPM with a lifestyle program led by a community health worker (CHW). The study will examine whether the enhanced program helps women better control their blood pressure, lowers their average resting blood pressure, improves heart health risk factors (such as weight, diet, physical activity), supports mental well-being, and reduces emergency department visits and hospital readmissions by 6 months after delivery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Enhanced Care Group — During the first 6 weeks after delivery, participants in the enhanced care group will receive the same RBPM program described above. Starting at 7 weeks after delivery, women whose BP was normal during the first 6 weeks will stop BP monitoring. Women whose BP remains high (above 130/80 mmHg) or who are still taking BP medications will continue monitoring their BP three times per week until 6 months after delivery. Nurses will continue to provide reminders and support. In addition, participants in the enhanced care group will receive 10-week health coaching led by a community health worker (CHW). This will include 10 weekly coaching calls by CHW. The coaching will focus on heart-healthy lifestyle behaviors that help lower BP and improve heart health. These include healthy weight loss goals (1-3 pounds per week), better nutrition, gradually increasing physical activity, stress management, and quitting tobacco use. Participants will be reminded to watch the weekly v
  • Behavioral: Remote Blood Pressure Monitoring alone — Participants in this group will receive an automatic blood pressure (BP) cuff and wear the cuff for 6 weeks after childbirth. Participants will be asked to measure their BP every day during the first 2 weeks after delivery and 3-5 times per week during weeks 3-6. BP readings will be sent automatically to the electronic medical record. A clinical decision support system will identify missing readings or possible care needs. A nurse will send reminders, contact participants to discuss symptoms or medications, and refer them to their primary care providers when needed. At 7 weeks after delivery, BP monitoring and text messages will stop, and BP cuffs will be collected. After the initial 6 weeks after delivery, participants in the RBPM-only group will receive weekly messages with publicly available information about heart disease risk after high blood pressure in pregnancy, healthy lifestyle tips from professional organizations, and guidance on infant development.

Primary Outcomes

  • Rates of Blood Pressure Control (6 months)
  • Change in mean systolic BP (mmHg), diastolic BP (mmHg), arterial pressure (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-24
Completion: 2029-07-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of South Carolina
Collaborators: Prisma Health-Midlands
Contact Information
Study Contact:
Jihong Liu, Sc.D
18037776854
jliu@mailbox.sc.edu
Andrew Mather, MD
8034349669
andrew.mather4@prismahealth.org
Jihong Liu, ScD
8037776854
jliu@mailbox.sc.edu
University of South Carolina
Interventions
  • Behavioral: Enhanced Care Group — During the first 6 weeks after delivery, participants in the enhanced care group will receive the same RBPM program described above. Starting at 7 weeks after delivery, women whose BP was normal during the first 6 weeks will stop BP monitoring. Women whose BP remains high (above 130/80 mmHg) or who are still taking BP medications will continue monitoring their BP three times per week until 6 months after delivery. Nurses will continue to provide reminders and support. In addition, participants in the enhanced care group will receive 10-week health coaching led by a community health worker (CHW). This will include 10 weekly coaching calls by CHW. The coaching will focus on heart-healthy lifestyle behaviors that help lower BP and improve heart health. These include healthy weight loss goals (1-3 pounds per week), better nutrition, gradually increasing physical activity, stress management, and quitting tobacco use. Participants will be reminded to watch the weekly v
  • Behavioral: Remote Blood Pressure Monitoring alone — Participants in this group will receive an automatic blood pressure (BP) cuff and wear the cuff for 6 weeks after childbirth. Participants will be asked to measure their BP every day during the first 2 weeks after delivery and 3-5 times per week during weeks 3-6. BP readings will be sent automatically to the electronic medical record. A clinical decision support system will identify missing readings or possible care needs. A nurse will send reminders, contact participants to discuss symptoms or medications, and refer them to their primary care providers when needed. At 7 weeks after delivery, BP monitoring and text messages will stop, and BP cuffs will be collected. After the initial 6 weeks after delivery, participants in the RBPM-only group will receive weekly messages with publicly available information about heart disease risk after high blood pressure in pregnancy, healthy lifestyle tips from professional organizations, and guidance on infant development.
Study Locations (1 sites)
University of South Carolina, Columbia, South Carolina 29208 United States
Eligibility Criteria
Inclusion Criteria: * 28 weeks gestation * A current hypertensive disorders in pregnancy or chronic hypertension * Singletons * Access to phone * Plan to deliver at Prisma Health-Midlands Hospital. Exclusion Criteria: * Multiples * Fetal anomaly * Don't speak English * Already delivered a baby greater than 14 days ago.
Conditions Breast Cancer
Phase NA
Enrollment 258
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, open-label study compares endoscopic skin-sparing mastectomy (E-SSM) with conventional mastectomy (CM) in female patients with unilateral invasive breast cancer (T1-4aN0-3M0). The primary objective is to evaluate differences in postoperative wound complications and patient satisfaction, with secondary outcomes including breast appearance and oncological safety. Eligible patients have a breast volume ≤ cup C and no/mild ptosis (grade I-II). A total of 258 participants (129 per group) will be enrolled across multiple centers and randomized by site. This study aims to provide evidence for selecting optimal endoscopic surgical strategies, address the evidence gap for E-SSM without immediate reconstruction, and advance the precision of breast cancer surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic skin-sparing mastectomy — Endoscopic skin-sparing mastectomy (E-SSM). Under endoscopic assistance, the breast skin and partial subcutaneous tissue are preserved, while the breast parenchyma, and nipple-areola complex are resected according to oncological principles. This approach aims to maintain breast envelope integrity while ensuring oncological safety.
  • Procedure: Conventional mastectomy — Conventional mastectomy (CM). The breast tissue, nipple-areola complex, and a full thickness of skin and subcutaneous tissue within the traditional resection range are removed. This is the standard surgical approach for breast cancer.

Primary Outcomes

  • Wound Complication Rate (occurring prior to completion of adjuvant chemotherapy and radiotherapy, about 6-12 months postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-05
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 258 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • Shicheng Su (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Shicheng Su
+86 13631304227
sushch@mail.sysu.edu.cn
Shicheng Su
+86 13631304227
sushch@mail.sysu.edu.cn
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Interventions
  • Procedure: Endoscopic skin-sparing mastectomy — Endoscopic skin-sparing mastectomy (E-SSM). Under endoscopic assistance, the breast skin and partial subcutaneous tissue are preserved, while the breast parenchyma, and nipple-areola complex are resected according to oncological principles. This approach aims to maintain breast envelope integrity while ensuring oncological safety.
  • Procedure: Conventional mastectomy — Conventional mastectomy (CM). The breast tissue, nipple-areola complex, and a full thickness of skin and subcutaneous tissue within the traditional resection range are removed. This is the standard surgical approach for breast cancer.
Study Locations (1 sites)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 75 years * Pathologically confirmed invasive breast cancer * Clinical stage cT1-4a N0-3 M0 * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Unilateral breast cancer * Left ventricular ejection fraction (LVEF) ≥ 50% * Hematological and renal function with the following parameters: White blood cell count ≥ 3.0 × 10⁹/L; Neutrophil count ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum creatinine ≤ 1.5 × upper limit of normal (ULN) * No planned breast reconstruction Exclusion Criteria: * Tumor invasion of the skin * Diffuse malignant microcalcifications * Breast cancer during pregnancy or lactation * History of another primary malignancy * Severe cardiopulmonary, hepatic or renal dysfunction, or other significant systemic diseases
Conditions Gestational Diabetes Mellitus in Pregnan...
Phase NA
Enrollment 220
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial aims to evaluate the effectiveness of a Behavioral Modification Working (BMW) Toolkit in improving glycemic control and blood pressure among pregnant women diagnosed with both GDM and PIH.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Modification Working (BMW) Toolkit — Structured behavioral intervention consisting of 7-8 sessions delivered by a trained health educator focusing on dietary modification, physical activity promotion, sleep hygiene, and self-care practices for pregnant women with gestational diabetes mellitus and pregnancy-induced hypertension, provided in addition to routine antenatal care.
  • Other: Routine Antenatal Care — Standard antenatal care provided according to hospital protocol for gestational diabetes mellitus and pregnancy-induced hypertension.

Primary Outcomes

  • Fasting Blood Glucose (Baseline and 40 weeks gestation)
  • Blood Pressure (Baseline and 36 weeks gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-21
Completion: 2027-01-15
Eligibility
Age: 15 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of the Punjab
Contact Information
Study Contact:
Assia Riaz, PhD Public Health
+92 322 4071468
assia.res.iscs@pu.edu.pk
Dr Muhammad Navid Tahir, Public Health
+92 333 4245831
navid.iscs@pu.edu.pk
Rameesa Liaqat
03349716254
rameesaliaqat1998@gmail.com
Shaikh Zayed Hospital
Interventions
  • Behavioral: Behavioral Modification Working (BMW) Toolkit — Structured behavioral intervention consisting of 7-8 sessions delivered by a trained health educator focusing on dietary modification, physical activity promotion, sleep hygiene, and self-care practices for pregnant women with gestational diabetes mellitus and pregnancy-induced hypertension, provided in addition to routine antenatal care.
  • Other: Routine Antenatal Care — Standard antenatal care provided according to hospital protocol for gestational diabetes mellitus and pregnancy-induced hypertension.
Study Locations (2 sites)
Shaikh Zayed Hospital, Lahore, Punjab Province 54000 Pakistan
Sir Ganga Ram Hospital, Lahore, Punjab Province 54000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Pregnant women aged 15-49 years. * Gestational age between 16 and 20 weeks at enrolment. * Diagnosed with both gestational diabetes mellitus (GDM) and pregnancy-induced hypertension (PIH). * At least one prior antenatal visit at the study site. Exclusion Criteria: * Pre-existing diabetes mellitus or chronic hypertension prior to pregnancy. * Pre-existing renal disease, thyroid disease, or major hematological disorders. * Multiple pregnancy (e.g., twins, triplets). * Severe psychiatric illness.
Conditions Asthma (Diagnosis)
Phase NA
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Bronchial asthma is a chronic inflmmatory airway disease characterized by recurrent episodes of dyspnea, wheezing, and airflow limitation. Dysfunctional breathing pattern and chronic hyperventilation

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Alternative Nostril Breathing Technique along with standard pharmacological management — Patients in this group will receive alternative nostril breathing technique along with standard pharmacological management. A total 4 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home. Alternative nostril breathing will be performed in sitting position. The patient will be asked to place their right thumb to gently close their right nostril. Inhale slowly for 4 sec deeply through left nostril and hold breath for 2-3 sec. Release right nostril and use your right ring finger to close your left nostril. Exhale slowly 6 sec and completely through right nostril.Inhale slowly 4 sec and deeply through right nostril.Then hold breath for 2-3 sec. Patients will be asked to release the left nostril and use their right thumb to close their right nostril. Exhale slowly and completely through left nostril over 6 sec.Repeat the cycle. Pharmacological management: Patient will receive medications as per prescribed by pulmonologist
  • Other: Buteyko breathing along with pharmacological management — Patient in this group will receive Buteyko breathing along with pharmacological management. A total 4 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days will be done by patients at home. The patient will sit comfortably in upright position. The patients will be give following instructions. Breathe normally for 2-3 minutes (nasal inhalation and nasal exhalation). After relax exhale, hold your breath, use index finger and thumb to plug nose. Retain your breath until you feel the urge to breathe (first sign of air hunger) then inhale. Breath normally for 10 sec. Repeat several times. Pharmacological management: Patient will receive medications as prescribed by pulmonologist

Primary Outcomes

  • Control Pause (04 weeks)
  • Dyspnea (04 weeks)
  • Pulmonary Function Test (04 weeks)
  • Asthma Control (04 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-28
Completion: 2026-05-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Foundation University Islamabad
Contact Information
Study Contact:
Maryam Arooj, MSPT-CPPT
+923428190176
maryamarooj418@gmail.com
Zara Khalid, PhD
+92333-5415822
zara.khalid@fui.edu.pk
Zara Khalid, PhD
+92333-5415822
zara.khalid@fui.edu.pk
Foundation University Islamabad
Interventions
  • Other: Alternative Nostril Breathing Technique along with standard pharmacological management — Patients in this group will receive alternative nostril breathing technique along with standard pharmacological management. A total 4 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home. Alternative nostril breathing will be performed in sitting position. The patient will be asked to place their right thumb to gently close their right nostril. Inhale slowly for 4 sec deeply through left nostril and hold breath for 2-3 sec. Release right nostril and use your right ring finger to close your left nostril. Exhale slowly 6 sec and completely through right nostril.Inhale slowly 4 sec and deeply through right nostril.Then hold breath for 2-3 sec. Patients will be asked to release the left nostril and use their right thumb to close their right nostril. Exhale slowly and completely through left nostril over 6 sec.Repeat the cycle. Pharmacological management: Patient will receive medications as per prescribed by pulmonologist
  • Other: Buteyko breathing along with pharmacological management — Patient in this group will receive Buteyko breathing along with pharmacological management. A total 4 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days will be done by patients at home. The patient will sit comfortably in upright position. The patients will be give following instructions. Breathe normally for 2-3 minutes (nasal inhalation and nasal exhalation). After relax exhale, hold your breath, use index finger and thumb to plug nose. Retain your breath until you feel the urge to breathe (first sign of air hunger) then inhale. Breath normally for 10 sec. Repeat several times. Pharmacological management: Patient will receive medications as prescribed by pulmonologist
Study Locations (1 sites)
Foundation University Islamabad, Islamabad, Pakistan
Eligibility Criteria
Inclusion Criteria: * Age between 18-45 years * Both genders (male and female) * Grade 1-3 on mMRC scale of dyspnea * Asthma severity classes- intermediate,mild persistent and moderate persistent asthma (acc. to NAEPP National Asthma Education and Prevention Program guidlines 2020) Exclusion Criteria: * Patients having acute exerbation of COPD/status asthmaticus * Patients diagnosed with acute infection * Patients unable to follow command and instructions * Asthma patients with \>40sec control pause duration
Conditions Breast Cancer
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Brief Summary This is an open-label, randomized, phase II clinical study designed to evaluate neoadjuvant treatment regimens in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer. A total of 60 premenopausal, perimenopausal, and postmenopausal patients with HR+/HER2- breast cancer who meet the inclusion criteria will be enrolled. During the study, clinical information will be collected according to standard practice, including demographic data, tumor imaging, and pathological results (e.g., Ki-67). Investigator-assessed outcomes will be used as the final results. After 14 days of treatment, patients who provide consent will undergo a second biopsy to evaluate the rate of complete cell-cycle arrest. Safety assessments and imaging evaluations will be performed at treatment completion or upon study withdrawal. Informed consent must be obtained at each study center before participation. Treatment arms: Arm A (30 patients): Dalpiciclib 125 mg orally once daily on Days 1-21 of each 28-day cycle (3 weeks on, 1 week off), for 6 cycles Letrozole 2.5 mg orally once daily continuously for 6 cycles Entinostat 3 mg orally once weekly (Days 1-28 of each 28-day cycle), for 6 cycles Arm B (30 patients): Dalpiciclib 150 mg orally once daily on Days 1-21 of each 28-day cycle, for 6 cycles Letrozole 2.5 mg orally once daily continuously for 6 cycles Premenopausal and perimenopausal women will also receive ovarian function suppression (OFS), such as with a GnRHa agent. After signing informed consent, patients will begin neoadjuvant therapy with dalpiciclib plus entinostat and letrozole ± OFS. Ultrasound assessments will be conducted every two treatment cycles and before surgery under the same imaging conditions as baseline. Bone scans will be performed at the end of neoadjuvant treatment. MRI of the breast will be performed at baseline, after two cycles, and before surgery to assess treatment efficacy. Treatment discontinuation will occur if toxicity is intolerable, consent is withdrawn, or the investigator determines it is necessary. Adjuvant therapy: After surgery, patients will receive physician's choice of therapy (TPC). Safety follow-up: Patients will be followed until they start another anticancer therapy, all adverse events have resolved to Grade 0-1 or baseline level, or death-whichever occurs first.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: entinostat — Entinostat is added in the experimental arm, while the control arm does not receive Entinostat.
  • Drug: Dalpiciclib — Dalpiciclib is both added in the experimental arm and control arm.
  • Drug: Letrozole — Letrozole is both added in the experimental arm and control arm.

Primary Outcomes

  • ORR (From baseline to end of neoadjuvant therapy (approximately 6 cycles, ~24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-12
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hebei Medical University Fourth Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Principal Investigators:
  • Zhenchuan Song (STUDY_CHAIR) - he Fourth Hospital of Hebei Medical University
Contact Information
Study Contact:
Zhenchuan Song
18531117857
songzhch@hotmail.com
Zhenchuan Song
185 31117857
songzhch@hotmail.com
The Fourth Hospital of Hebei Medical University
Interventions
  • Drug: entinostat — Entinostat is added in the experimental arm, while the control arm does not receive Entinostat.
  • Drug: Dalpiciclib — Dalpiciclib is both added in the experimental arm and control arm.
  • Drug: Letrozole — Letrozole is both added in the experimental arm and control arm.
Study Locations (1 sites)
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000 China
Eligibility Criteria
Inclusion Criteria: \- Inclusion Criteria 1. Female patients aged ≥18 and \<75 years, including postmenopausal, premenopausal, or perimenopausal. Postmenopause is defined as:Prior bilateral oophorectomy, or age ≥60 years; orAge \<60 years, natural postmenopause (spontaneous cessation of menses for ≥12 months without other pathological or physiological cause) with estradiol (E2) and FSH in postmenopausal range; orPremenopausal or perimenopausal women willing to receive LHRH agonist (OFS) therapy during the study. 2. Histologically confirmed estrogen receptor (ER)-positive (\>10%) invasive breast cancer, regardless of PR expression, and HER2-negative according to the 2018 ASCO/CAP HER2 testing guidelines (IHC 0+ or IHC 2+ with ISH-negative, amplification ratio \<2.0). 3. At least one measurable lesion according to RECIST 1.1; clinical stage T1c-T2, cN1-2, or T3-T4, cN0-2. 4. No prior anticancer therapy for breast cancer, including chemotherapy,endocrine therapy, or targeted therapy. 5. Ability to swallow oral medications. 6. Baseline left ventricular ejection fraction (LVEF) ≥50%. 7. Adequate organ function:Hematology (within 1 week):Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;White blood cell count (WBC) ≥3.0 × 10⁹/L;Platelet count ≥90 × 10⁹/L;Hemoglobin ≥90 g/L Liver and kidney function (within 1 week):Total bilirubin (TBIL) ≤ upper limit of normal (ULN);ALT and AST ≤1.5 × ULNBUN and creatinine ≤1.5 × ULN, with creatinine clearance ≥60 mL/min (Cockcroft-Gault formula) 8. ECG: Corrected QT interval ≤470 ms (12-lead ECG) 9. Willingness and ability to undergo all required biopsy procedures. 10. Women of childbearing potential must have a negative pregnancy test before study entry and agree to use medically acceptable contraception during the study; postmenopausal women are exempt. 11. Voluntary participation with signed informed consent, good compliance, and willingness to adhere to follow-up requirements. Exclusion Criteria: \- Exclusion Criteria 1. Pregnant or breastfeeding women, or women with a positive pregnancy test at baseline; women of childbearing potential unwilling to use effective contraception during the study. 2. Bilateral breast cancer or inflammatory breast cancer. 3. Stage IV (metastatic) breast cancer at initial diagnosis. 4. History of congestive heart failure, unstable angina, significant arrhythmia, or myocardial infarction. 5. Active pulmonary disease, including interstitial lung disease, pneumonia, pulmonary fibrosis, or other acute lung conditions. 6. Significant liver disease, such as acute or fulminant hepatitis, impaired coagulation factor synthesis, or other severe hepatic dysfunction. 7. For patients positive for HBsAg or HBV core antibody, peripheral blood HBV DNA must be \<1×10³ IU/mL to be eligible. 8. Any concurrent disease or condition that may interfere with study participation or affect patient safety (e.g., active or uncontrolled infection). 9. Other invasive malignancies (including second primary breast cancer) that may interfere with study outcomes or compliance. 10. Prior chemotherapy, endocrine therapy, or biologic therapy for breast cancer (except diagnostic biopsy for primary breast cancer). 11. Major surgery within 4 weeks prior to study entry or unresolved significant medical conditions. 12. Tumors that are non-measurable during the study treatment. 13. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation.